CD73, Avi-His-Tag (Mouse) Recombinant

Only %1 left
Catalog #
72523
As low as $145 *

Cat # Size Price*

Qty
*US Pricing only. For international pricing, please contact your local distributor.
Purchase
Description

Recombinant mouse CD73 (5'-nucleotidase), encompassing amino acids 29-549. This construct contains a C-terminal Avi-His-tag (6xHis). This recombinant protein was affinity purified.

Synonyms
5'-nucleotidase; ecto-5'-nucleotidase; 5'-NT; eNT; NT; Nt5
Product Info
Storage and Usage
Citations
Species
Mouse
Construct
CD73 (Mouse) (29-549-Avi-His)
Host Species/Expression System
HEK293
Purity

≥90

Format
Aqueous buffer solution
Formulation
8 mM Phosphate, pH 7.4, 110 mM NaCl, 2.2 mM KCl, and 20% glycerol.
MW
61 kDa + glycans
Amino Acids
29-549
Glycosylation
This protein runs at a higher MW by SDS-PAGE due to glycosylation.
Specific Activity

≥20 nmol/min/µg

Genbank #
NM_011851
UniProt #
Q61503
Tag(s)
Avi-His-Tag
Background

CD73, or cluster of differentiation 73, is an enzyme which hydrolyzes AMP to adenosine. Increased concentrations of adenosine in the microenvironment has an immunosuppressive effect and promotes tumor cell growth.

Adenosine can enhance tumor growth via two mechanisms – 1) binding of adenosine to A2A and A2B receptors expressed on tumor cells directly promotes tumor cell proliferation and 2) binding of adenosine to A2A and A2B receptors on immune cells such as also  inhibits the activity of pro-inflammatory, anti-tumor immune cells like CD4+ T Cells, CTLs, dendritic cells, NK cells, while and activating immunosuppressant cells like Tregs, MDSCs and TAMs.

Development of inhibitory antibodies and small molecules against CD73 could serve as a new therapeutic strategy in the treatment of cancer. In preclinical models have provided proof of concept for this hypothesis as Inhibition of CD73 in mouse models has resulted in anti-tumor effects, providing proof of concept for this hypothesis.

CD73/CD39 Immunotherapy

References
1. Deaglio, S. et al., J. Exp. Med. 2007; 204(6): 1257-1265. 2. Thompson, L.F., et al., J. Exp. Med. 2004; 200(11): 1395-1405.